Senju Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Nippon Chemiphar Co., Ltd.

Senju Usa, Inc.

Jun Inoue

Mitsuyoshi Azuma

Masayuki Nakamura

Yoshikuni Nakamura

Ikuko Hanano

Yuka Yoshida

Chiho Fukiage

Yuji Sakamoto

Yukuo Yoshida

Yoshiko Takayama

Hideo Terayama

Yusuke Sakai

Masazumi Yamaguchi

Tapan Shah

Yoshihisa Shirasaki

Hiroyuki Miyashita

Ying-She Cui

A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

Pharmaceutical containing PPAR-delta agonist

An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR&#x3b1; or &#x3b4; agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR&#x3b1; or &#x3b4; agonist as an active ingredient.

Pharmaceutical comprising PPAR agonist

Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

Pharmaceutical containing PPAR delta agonist

The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.

Ophthalmic composition

The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye. 

Agent for repairing corneal sensitivity containing amide compound

The present invention provides a preparation containing a compound of the formula (I) wherein Ris an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; Rand Rare the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or Rand Rin combination form a ring having 3 to 7 carbon atoms; and Ris a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.

Drug composition comprising dipeptidyl aldehyde derivative

The present invention provides a compound represented by the formula (I): (wherein

Alpha-ketoamide derivative, and production method and use thereof

Corneal perception recovery drug containing amide compound

A compound represented by the following formula (I) wherein Rand Rare each a lower alkyl group optionally having substituents, which has a calpain inhibitory activity, or a salt thereof is provided.

Hydroxymorpholinone derivative and medicinal use thereof

A compound represented by the following formula (I) wherein Ris a lower alkyl group, Ris a hydrogen, a halogen, a cyano group, a lower alkyl group or a lower alkoxy group, and n is 0 or 1, which has a calpain inhibitory activity, is provided.

Cyclic hemiacetal derivative and use thereof

The present invention provides a compound represented by the formula (I):wherein R, Rand Reach represents a lower alkyl group.

&#x3b1;-ketoamide derivative and use thereof

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity[wherein Rand Rare the same or different, and denote a lower alkyl group or a phenyl group, or Rand Rare taken together to form a ring, Rdenotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR(Ris hydrogen or optionally substituted lower alkyl group), or NBR(Ris aryl group, and Bis carbonyl group or sulfonyl group), and Bdenotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

Imidazolidinedione derivatives and use thereof as drugs

Angiogenesis inhibitor

A pharmaceutical composition for the prophylaxis and therapy of a disease arising from ocular fundus tissue cytopathy such as retinochoroidal disease, glaucoma, and posterior complication arising form photocoagulation, which contains, as an active ingredient, a compound of formula (I) wherein R represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R and R may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R and R may jointly form a ring having 3 to 7 carbon atoms; and R represents a lower alkyl group which substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Kobe, Japan

Jun Inoue